April 9, 2025 - Global implementation of blood tests for Alzheimer’s disease (AD) would be facilitated by easily scalable, cost-effective and accurate tests. In the present study, we evaluated plasma phospho-tau217 (p-tau217) using predefined biomarker cutoffs. The study included 1,767 participants with ...

April 13, 2025 - The p-Tau217 biomarker is one of the most exciting advances in neurology for decades, giving us a new opportunity to accurately predict and potentially prevent (or at least substantially delay) MCI and Alzheimer’s.

"The future of assessing risk or diagnosing AD will likely include a variety of testing modalities and biomarkers, including blood, to help clinicians identify patients in the early stages of disease progression. When examined with cognitive test results, p-tau217 has the potential to aid diagnosis, and will play a valuable role in assessing patients with cognitive impairment, especially when combined with other tests." Nearly 7 million Americans have Alzheimer's, the most prevalent dementia, a number projected to reach 14 million by 2060.

P-tau217 has also shown utility in distinguishing AD from other neurodegenerative diseases [26,67]. Reduced plasma p-tau217 extracellular vesicles (EVs) have been observed in AD compared to non-AD controls while smaller p-tau217 EVs have been found in AD compared to non-AD dementia [77]. A model combining patient age with number and size of EVs carrying p-tau217 discriminated AD from non-AD controls and non-AD dementia with high accuracy [77]. While elevated p-tau217 has been observed in AD and other neurodegenerative diseases, p-tau217 distinguished AD from disorders such as primary progressi

© 2025 The Alzheimer's Association. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. ... P‐tau217 is emerging as the most accurate blood‐based biomarker (BBBM) for the diagnosis of Alzheimer's disease (AD) pathology, with elevated levels correlating with β‐amyloid and tau pathology, as confirmed by PET scans and cerebrospinal fluid analysis.

2 weeks ago - Blood biomarkers have emerged as accurate tools for detecting Alzheimer’s disease (AD) pathology, offering a minimally invasive alternative to traditional diagnostic methods such as imaging and cerebrospinal fluid (CSF) analysis. Yet, the logistics surrounding venipuncture for blood collection, although considerably simpler than the acquisition of imaging and CSF, require precise processing and storage specific to AD biomarkers that are still guided by medical personnel.

September 22, 2025 - Discussion: Plasma biomarkers p-tau181, p-tau217, and GFAP demonstrate clinical utility in distinguishing AD from normal cognition, suggesting that blood-based testing may serve as a feasible screening tool for early identification of AD in very elderly populations. With the rising incidence of Alzheimer’s disease (AD) in China, early screening and diagnosis have become increasingly important.

March 31, 2025 - “I believe we will use blood-based p-tau217 to determine whether an individual has Alzheimer’s disease, but MTBR-tau243 will be a highly valuable complement in both clinical settings and research trials,” said Hansson. “When both of these biomarkers are positive, the likelihood that Alzheimer’s is the underlying cause of a person’s cognitive symptoms increases significantly, compared to when only p-tau217 is abnormal.

In the study, 1,213 patients were tested with the PrecivityAD2 test (known as “APS2”). It uses a combination of (1) plasma phosphorylated-tau217 to not-phosphorylated-tau217 ratio (known as %p-tau217) and (2) the ratio of two types of amyloid (Aβ42/Aβ40), and it significantly outperformed clinicians in this study. Among 698 patients seen at memory clinics, APS2 was around 90% accurate at identifying Alzheimer’s disease while specialists were 73% accurate.

November 25, 2025 - Depending on the patient’s age, clinical syndrome, and APOE ε4 carrier status, p-tau217 demonstrated >95% PPV in ruling in AD and>90% negative predictive value NPV for ruling it out. Further, the authors were able to deduce that cutting-edge assays like GFAP and NfL complement p-tau217, highlighting the broader potential for multiplex diagnostic panels. These findings are impactful as they help answer questions about the clinical value of blood-based biomarker tests. Clinicians have traditionally relied on outdated methods to diagnose AD by observing cognitive decline, at which point the disease has already likely caused irreversible brain damage.

August 25, 2025 - Blood-based biomarkers are ushering in a new era for Alzheimer’s Disease diagnosis and cognitive health, offering faster, less invasive options that expand access and hope. With advanced tools like the Alzheimer’s blood test measuring p-tau217, p-tau181, and the Aβ42/40 ratio, along with genetic insights from APOE genotype and supportive markers like Neurofilament Light Chain (NfL) and Glial Fibrillary Acidic Protein (GFAP), patients and providers now have powerful resources to evaluate memory loss, mild cognitive impairment (MCI), and ongoing cognitive decline.

December 9, 2025 - Studies using well-defined patient cohorts demonstrate the potential for blood biomarkers of core AD pathology- such as phosphorylated tau (p-tau) and Aβ -as well as neurodegeneration markers such as neurofilament light chain (NfL).6-9 These studies show that plasma biomarkers in individuals with AD exhibit abnormal levels and closely reflect CSF measures, underscoring their diagnostic utility.10 This supports the use of blood biomarkers as valuable tools for early and accurate diagnosis, prognosis, and for tracking disease progression and treatment response in clinical settings.11 Moreover,

May 22, 2025 - This biomarker supports scalable AD screening in secondary healthcare settings, overcoming accessibility and cost barriers in resource-limited environments. • Flow cytometry-measured P-tau181/Aβ42 achieves 96.2% accuracy in distinguishing AD from controls. • P-tau181/Aβ42 differentiates AD from non-AD dementias (86%–88% accuracy), validated against SIMOA P-tau217.

1 month ago - Dementia represents a major global public health challenge, with Alzheimer’s disease (AD) as its most common cause. Until recently, verification of AD neuropathological changes, amyloid-β plaques, and tau tangles required cerebrospinal fluid analysis or positron emission tomography, which are impractical for population screening. Blood-based biomarkers now enable detection of pTau217, a marker tightly linked to downstream tau pathology following amyloid-β accumulation.

This biomarker supports scalable AD screening in secondary healthcare settings, overcoming accessibility and cost barriers in resource-limited environments. Keywords: Alzheimer’s disease, plasma biomarkers, P-tau181/Aβ42, SIMOA, flow cytometry · • Flow cytometry-measured P-tau181/Aβ42 achieves 96.2% accuracy in distinguishing AD from controls. • P-tau181/Aβ42 differentiates AD from non-AD dementias (86%–88% accuracy), validated against SIMOA P-tau217.

September 13, 2024 - Plasma biomarkers offer an opportunity as a cost- and time-effective tool that is minimally invasive for screening and diagnosis, stratification, monitoring disease progression, and assessing treatment response. Biomarkers that have been proposed include amyloid-beta (Aβ40, Aβ42, and their ratio), phosphorylated tau (p-tau181 and p-tau217), glial fibrillary acidic protein (GFAP), and neurofilament light (NfL) (reviewed in [1]). The sensitivity and specificity of these biomarkers is an area of active research. In particular, p-tau217 has been demonstrated to be a valuable biomarker for predicting cognitive decline and monitoring treatment efficacy in response to DMT [8, 9].

March 18, 2025 - Furthermore, ratio aspects evaluated in Aβ42/Aβ40, P-tau217/Aβ42, P-tau181/Aβ42 and T-tau/Aβ42 demonstrated varied sensitivities and specificities. Noteworthy, P-tau217 and P-tau217/Aβ42 exhibited similar performance for distinguishing AD and CUC, which were consistent with study of Olvera-Rojas et al. (2025). These discoveries suggest that these metrics hold potential as diagnostic biomarkers within the Chinese population.

Studies using well-defined patient cohorts demonstrate the potential for blood biomarkers of core AD pathology- such as phosphorylated tau (p-tau) and Aβ -as well as neurodegeneration markers such as neurofilament light chain (NfL).6-9 These studies show that plasma biomarkers in individuals with AD exhibit abnormal levels and closely reflect CSF measures, underscoring their diagnostic utility.10 This supports the use of blood biomarkers as valuable tools for early and accurate diagnosis, prognosis, and for tracking disease progression and treatment response in clinical settings.11 Moreover,

In a prospective cohort, plasma p-tau217 was more strongly associated with AΒ positivity (AUC, 0.94; 95% CI, 0.90–0.97) than p-tau181, p-tau231, N-terminal tau, glial fibrillary acidic protein (GFAP), or NfL, placing it as a frontrunner for a blood-based diagnostic screening test.10 The ALZpath plasma p-Tau217 Simoa assay (Carlsbad, CA) accurately identified elevated AΒ (AUC, 0.92; 95% CI, 0.89–0.99) and tau pathology (AUC, 0.93; 95% CI, 0.84–0.99) across all cohorts,27 had reproducible cutoffs across cohorts, and detected longitudinal changes, even in preclinical stages.

P-tau217 is currently the most promising diagnostic marker for AD, demonstrating greater than 90% accuracy for detecting AD pathology. This has led to the development of tests, such as the LucentAD p-tau217 test from Lucent Diagnostics. In clinical research, however, Simoa has already proven invaluable. Disease-modifying AD therapies have emerged recently, and in trials demonstrating their efficacy, Simoa-based assays were used to track biomarkers to assess drug activity.